CY1119052T1 - Νεες φαρμακοτεχνικες μορφες εμβολιου που περιλαμβανουν ανοσοενισχυτικα που περιεχουν σαπωνινη - Google Patents
Νεες φαρμακοτεχνικες μορφες εμβολιου που περιλαμβανουν ανοσοενισχυτικα που περιεχουν σαπωνινηInfo
- Publication number
- CY1119052T1 CY1119052T1 CY20161101013T CY161101013T CY1119052T1 CY 1119052 T1 CY1119052 T1 CY 1119052T1 CY 20161101013 T CY20161101013 T CY 20161101013T CY 161101013 T CY161101013 T CY 161101013T CY 1119052 T1 CY1119052 T1 CY 1119052T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical forms
- new pharmaceutical
- containing immune
- vaccine including
- saponin containing
- Prior art date
Links
- 239000001397 quillaja saponaria molina bark Substances 0.000 title 1
- 229930182490 saponin Natural products 0.000 title 1
- 150000007949 saponins Chemical class 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 2
- 244000052769 pathogen Species 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000000287 crude extract Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 239000013613 expression plasmid Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει ένα νέο γαλάκτωμα ελαίου σε ύδωρ (O/W), με αυξημένη σταθερότητα παρουσία βακτηριακών ή ιικών εναιωρημάτων, ειδικώς αυτών που είναι συμπυκνωμένα και μη-καθαρισμένα (ακατέργαστα εκχυλίσματα) ή ελαχίστως καθαρισμένα. Το γαλάκτωμα της παρούσας εφεύρεσης μπορεί να δρα ως έκδοχο για την απελευθέρωση μιας φαρμακευτικής σύνθεσης που περιλαμβάνει τουλάχιστον ένα ανοσογόνο και, ειδικότερα, ανοσογόνο που επιλέγεται από την ομάδα που αποτελείται από απενεργοποιημένο παθογόνο, εξασθενημένο παθογόνο, υπομονάδα, ανασυνδυασμένο φορέα έκφρασης και πλασμίδιο ή συνδυασμούς αυτών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24117109P | 2009-09-10 | 2009-09-10 | |
PCT/US2010/048256 WO2011031850A1 (en) | 2009-09-10 | 2010-09-09 | New vaccine formulations comprising saponin-containing adjuvants |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119052T1 true CY1119052T1 (el) | 2018-01-10 |
Family
ID=43063042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161101013T CY1119052T1 (el) | 2009-09-10 | 2016-10-12 | Νεες φαρμακοτεχνικες μορφες εμβολιου που περιλαμβανουν ανοσοενισχυτικα που περιεχουν σαπωνινη |
Country Status (26)
Country | Link |
---|---|
US (2) | US9107859B2 (el) |
EP (1) | EP2475384B1 (el) |
JP (1) | JP5759463B2 (el) |
KR (1) | KR101746880B1 (el) |
CN (2) | CN107213461B (el) |
AR (2) | AR078169A1 (el) |
AU (1) | AU2010292233B2 (el) |
CA (1) | CA2773486C (el) |
CO (1) | CO6531435A2 (el) |
CY (1) | CY1119052T1 (el) |
DK (1) | DK2475384T3 (el) |
ES (1) | ES2600929T3 (el) |
HR (1) | HRP20161414T1 (el) |
HU (1) | HUE030664T2 (el) |
LT (1) | LT2475384T (el) |
MX (2) | MX2012002814A (el) |
MY (1) | MY157607A (el) |
NZ (1) | NZ598645A (el) |
PL (1) | PL2475384T3 (el) |
PT (1) | PT2475384T (el) |
RU (1) | RU2555342C2 (el) |
SG (1) | SG179037A1 (el) |
SI (1) | SI2475384T1 (el) |
SM (1) | SMT201600394B (el) |
UA (1) | UA107940C2 (el) |
WO (1) | WO2011031850A1 (el) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011012362A (es) * | 2009-05-19 | 2012-04-19 | Bioproperties Pty Ltd | Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usoz de la misma. |
CN102648003B (zh) * | 2009-10-09 | 2016-01-13 | 儿童医疗中心有限公司 | 选择性裂解的全细胞疫苗 |
CN102226153B (zh) * | 2011-05-10 | 2012-12-05 | 黑龙江大学 | 用于生成污染菌抗血清的免疫原的制备方法 |
EP3744833A1 (en) * | 2011-06-28 | 2020-12-02 | Leukocare Ag | Stabilisation method for viruses |
MX353786B (es) | 2012-02-14 | 2018-01-29 | Merial Inc | Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas. |
RU2521513C1 (ru) * | 2013-04-09 | 2014-06-27 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Применение этония в качестве адъюванта для производства сорбированной противоящурной вакцины |
EP2994162B1 (en) | 2013-05-08 | 2021-04-07 | Pharmgate Biologics Inc. | Vaccine for pcv2 and mycoplasma |
US9713639B2 (en) | 2014-05-19 | 2017-07-25 | Merial, Inc. | Recombinant spike protein subunit based vaccine for porcine epidemic diarrhea virus (PEDV) |
KR20170097116A (ko) * | 2015-01-16 | 2017-08-25 | 조에티스 서비시즈 엘엘씨 | 구제역 백신 |
CN104803850A (zh) * | 2015-04-29 | 2015-07-29 | 天津大学 | 一种酯类糖基相选择性亲油凝胶因子及其制备方法以及在油品胶凝中的应用 |
NZ739260A (en) | 2015-06-26 | 2019-09-27 | Boehringer Ingelheim Animal Health Usa Inc | Inactivated canine influenza vaccines and methods of making and uses thereof |
BR112018007093A2 (pt) | 2015-10-08 | 2019-01-15 | Pasteur Institut | vacina heteróloga atentada viva para leptospirose |
KR102153303B1 (ko) | 2015-11-23 | 2020-09-09 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | Fmdv 및 e2 융합 단백질 및 이의 용도 |
TWI760322B (zh) | 2016-01-29 | 2022-04-11 | 美商百靈佳殷格翰動物保健美國有限公司 | 重組腺病毒載體裝載之fmdv疫苗及其用途 |
US10485857B2 (en) | 2016-04-07 | 2019-11-26 | Boehringer Ingelheim Animal Health USA Inc. | Heartworm vaccine, methods and uses thereof |
JOP20190088A1 (ar) | 2016-10-21 | 2019-04-21 | Us Agriculture | نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها |
MA55772A (fr) | 2016-12-14 | 2022-03-02 | Boehringer Ingelheim Animal Health Usa Inc | Vecteurs hvt recombinants exprimant de multiples antigènes de pathogènes aviaires, et vaccins les contenant |
WO2018222874A1 (en) | 2017-05-31 | 2018-12-06 | Texas Tech University System | Methods and devices for the treatment of food allergies |
CN109806391A (zh) * | 2017-11-22 | 2019-05-28 | 西北民族大学 | 一种兽用疫苗免疫水溶性复合佐剂的制备方法及其应用 |
CN108853493A (zh) * | 2018-07-26 | 2018-11-23 | 中国人民解放军陆军军医大学 | 麦冬皂苷d及其纳米乳在制备疫苗佐剂中的应用 |
CN111658611B (zh) * | 2020-04-13 | 2021-06-01 | 四川大学 | 一种基于微乳的疫苗递送系统及其制备方法和应用 |
BR102021012953A2 (pt) * | 2021-06-29 | 2023-01-10 | Fabp Biotech Desenvolvimento Em Biotecnologia Ltda. | Composição de vacina veterinária contra helmintos, método para tratamento e prevenção de infecção causada por helmintos e uso |
US20230255886A1 (en) * | 2022-02-16 | 2023-08-17 | Chemical & Schutz High Performance Lubricants, S.A. De C.V. | Self-emulsionable mineral oil as a vehicle in vaccines for poultry |
CN116983396B (zh) * | 2023-08-09 | 2024-05-07 | 浙江省农业科学院 | 兔支气管败血波氏杆菌灭活疫苗乳剂及其制备和应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2777608A (en) | 1953-09-18 | 1957-01-15 | Sheffler James | Soap powder dispenser attachment |
GB1143545A (en) * | 1965-03-25 | 1969-02-26 | Wellcome Found | Injectable vaccine emulsions |
US3919411A (en) * | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
CA1331443C (en) * | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
EP0597852B2 (en) | 1990-05-29 | 2005-08-10 | Wyeth Holdings Corporation | Swine pneumonia vaccine and method for the preparation thereof |
EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
EP0580778B1 (en) * | 1991-04-19 | 1999-08-11 | LDS Technologies, Inc. | Convertible microemulsion formulations |
US5846805A (en) | 1991-08-26 | 1998-12-08 | Boehringer Ingelheim Animal Health, Inc. | Culture of swine infertility and respiratory syndrome virus in simian cells |
CA2085827C (en) * | 1991-12-23 | 2003-10-14 | Lucas A. T. Hilgers | Adjuvant composition containing synthetic hydrophobic lipopolysaccharide |
US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
US5695766A (en) | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
SK98695A3 (en) | 1993-02-08 | 1996-11-06 | Bayer Ag | Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines |
GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
FR2723740B1 (fr) | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
US5997881A (en) | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
US5866401A (en) | 1996-03-01 | 1999-02-02 | Schering Corporation | Porcine reproductive and respiratory syndrome vaccine |
US5980912A (en) | 1997-03-25 | 1999-11-09 | Zonagen, Inc. | Chitosan induced immunopotentiation |
ES2327693T3 (es) * | 1997-08-29 | 2009-11-02 | Antigenics Inc. | Composiciones que comprenden el adyvante qs-21 y polisorbato o ciclodextrina excipiente. |
WO1999011241A1 (en) * | 1997-09-05 | 1999-03-11 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
US6391314B1 (en) * | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
NZ508013A (en) | 1998-05-07 | 2003-08-29 | Corixa Corp | Adjuvant composition for use with an antigen in a vaccine composition |
TWI224107B (en) | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
CA2290220C (en) * | 1998-12-22 | 2013-11-19 | Pfizer Products Inc. | An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof |
US6943152B1 (en) * | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
GB0009735D0 (en) * | 2000-04-19 | 2000-06-07 | Zeneca Ltd | Formulation |
MY129765A (en) * | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
DE10113284A1 (de) | 2001-03-16 | 2002-10-02 | Heinrich Exner | Adjuvans-Emulsion und Verfahren zu deren Verwendung |
JP2006512401A (ja) * | 2001-06-05 | 2006-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ナノエマルジョンワクチン |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
US6642178B2 (en) * | 2001-11-14 | 2003-11-04 | North Dakota State University | Adjuvant blend for enhancing efficacy of pesticides |
US7378101B2 (en) * | 2001-12-21 | 2008-05-27 | Pfizer, Inc. | Vaccine for periodontal disease |
MXPA06000942A (es) * | 2003-07-24 | 2006-03-30 | Merial Ltd | Nuevas formulaciones de vacunas. |
US7691368B2 (en) * | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
HUE054868T2 (hu) * | 2005-12-29 | 2021-10-28 | Boehringer Ingelheim Animal Health Usa Inc | Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására |
JP2010512748A (ja) * | 2006-12-15 | 2010-04-30 | シェーリング−プラウ・リミテッド | インフルエンザウイルスを培養物中で複製するための方法 |
-
2010
- 2010-09-09 KR KR1020127009114A patent/KR101746880B1/ko active IP Right Grant
- 2010-09-09 MY MYPI2012001035A patent/MY157607A/en unknown
- 2010-09-09 LT LTEP10757885.8T patent/LT2475384T/lt unknown
- 2010-09-09 CN CN201710382912.3A patent/CN107213461B/zh active Active
- 2010-09-09 ES ES10757885.8T patent/ES2600929T3/es active Active
- 2010-09-09 PL PL10757885T patent/PL2475384T3/pl unknown
- 2010-09-09 UA UAA201204469A patent/UA107940C2/ru unknown
- 2010-09-09 PT PT107578858T patent/PT2475384T/pt unknown
- 2010-09-09 CN CN201080047645.0A patent/CN102573900B/zh active Active
- 2010-09-09 WO PCT/US2010/048256 patent/WO2011031850A1/en active Application Filing
- 2010-09-09 AU AU2010292233A patent/AU2010292233B2/en active Active
- 2010-09-09 SI SI201031314A patent/SI2475384T1/sl unknown
- 2010-09-09 SG SG2012016168A patent/SG179037A1/en unknown
- 2010-09-09 RU RU2012113814/15A patent/RU2555342C2/ru active
- 2010-09-09 US US12/878,630 patent/US9107859B2/en active Active
- 2010-09-09 JP JP2012528894A patent/JP5759463B2/ja active Active
- 2010-09-09 NZ NZ598645A patent/NZ598645A/en unknown
- 2010-09-09 CA CA2773486A patent/CA2773486C/en active Active
- 2010-09-09 MX MX2012002814A patent/MX2012002814A/es active IP Right Grant
- 2010-09-09 HU HUE10757885A patent/HUE030664T2/en unknown
- 2010-09-09 DK DK10757885.8T patent/DK2475384T3/en active
- 2010-09-09 EP EP10757885.8A patent/EP2475384B1/en active Active
- 2010-09-09 MX MX2014013363A patent/MX344863B/es unknown
- 2010-09-10 AR ARP100103323A patent/AR078169A1/es not_active Application Discontinuation
-
2012
- 2012-04-10 CO CO12058153A patent/CO6531435A2/es unknown
-
2015
- 2015-02-26 US US14/632,863 patent/US9730987B2/en active Active
-
2016
- 2016-10-12 CY CY20161101013T patent/CY1119052T1/el unknown
- 2016-10-27 HR HRP20161414TT patent/HRP20161414T1/hr unknown
- 2016-11-03 SM SM201600394T patent/SMT201600394B/it unknown
-
2021
- 2021-01-21 AR ARP210100138A patent/AR121096A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119052T1 (el) | Νεες φαρμακοτεχνικες μορφες εμβολιου που περιλαμβανουν ανοσοενισχυτικα που περιεχουν σαπωνινη | |
CY1125387T1 (el) | Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας, και μεθοδοι χρησης τους | |
CY1124254T1 (el) | Μεθοδοι και συνθεσεις για την προκληση προστατευτικης ανοσιας εναντι λοιμωξης ιου της ανθρωπινης ανοσοανεπαρκειας | |
CY1111378T1 (el) | Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
AR061894A1 (es) | Vacunas para malaria | |
BR112013009164A2 (pt) | capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada. | |
BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
BR112012021650A2 (pt) | "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina." | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
UY37198A (es) | Vacuna universal para enfermedades virales | |
CO7461135A2 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
MX2019007924A (es) | Vacunas contra la influenza. | |
BR112018015912A2 (pt) | vírus da vacina da síndrome respiratória e reprodutiva porcina | |
ZA202104747B (en) | Novel trypanosomal vaccine | |
BR112018013400A2 (pt) | vacina marcadora de pestivírus | |
UY31574A1 (es) | Vacunas contra la malaria | |
EA201401044A1 (ru) | Модифицированный вирус болезни марека и вакцины на его основе | |
GB2547835A (en) | Protective material | |
ZA202104746B (en) | Novel trypanosomal vaccine | |
BR112022008711A2 (pt) | Métodos para produzir uma vacina viral e reduzir o tamanho da partícula viral | |
CL2012001093A1 (es) | Vacuna de adn basada en la region que codifica la envoltura del virus de la fiebre amarilla fusionada a lamp; y antigeno de vacuna. | |
CY1116497T1 (el) | Λειτουργικα ιομορφα σωματιδια γριπης (vlps) | |
EA202191862A3 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
EA201992167A1 (ru) | Вакцина |